]>
IRCT20200905048630N4 IRCT 2023-05-24 Bandare-abbas University of Medical Sciences The effect of alpha lipoic acid administration on the outcomes of assisted reproductive therapy in patients with polycystic ovarian syndrome The effect of alpha lipoic acid administration on the outcomes of assisted reproductive therapy in patients with polycystic ovarian syndrome 2023-09-23 anticipated 40 Complete https://irct.ir/trial/69874 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Eligible patients (including 40 patients) are randomly assigned by a statistical expert using simple randomization method. In this method, the Random between function of the Excel program is used to generate a random number between the number 1 and 2. This work was repeated 40 times and thus a random sequence is obtained, Blinding description: The participants, researcher and data analyzer will not know how the groups will be assigned. 3 Poly cystic ovarian syndrome. Intervention 1: Intervention group: receiving oral alpha lipoic acid capsule 600 mg daily for 2 months. Intervention 2: Control group: Receiving a placebo( containing flour) daily for two months. Yes - There is a plan to make this available What will be shared: The data will be presented in the article after analysis When: 2025 To whom: Academic researchers and gynecologists and obstetricians Conditions: Application at the bedside in patients undergoing ICSI Where to obtain: corresponding author of the article How to obtain: Email to the corresponding author Comments:
public Dr Maryam Azizi Kutenaee
Shahid Mohammadi Hospital, Parastar Street
Bandar Abbas Iran (Islamic Republic of) 7916613885 +98 76 3333 0755 maryamazizikut86@gmail.com Bandare-abbas University of Medical Sciences scientific Dr Maryam Azizi Kutenaee
Shahid Mohammadi Hospital, Parastar Street
Bandar Abbas Iran (Islamic Republic of) 7916613885 +98 76 3333 0755 maryamazizikut86@gmail.com Bandare-abbas University of Medical Sciences Iran (Islamic Republic of) Women with polycystic ovary syndrome according to the Rotterdam criteria Women of reproductive age between 18 and 37 years Candidate for in vitro fertilization No endometriosis Absence of hydrosalpinx 18 years 37 years Female BMI≥30 Secondary causes of obesity (hypothyroidism, Cushing's syndrome) High grade endometriosis III and IV Thyroid diseases Salpingitis and hydrosalpinx Congenital adrenal hyperplasia Hyperprolactinemia Ovarian secretory tumors Receipt of OCPs (steroids or other drugs that affect ovarian function, insulin sensitivity, and lipid metabolism) in the past 3 months, except for standardized PCOS treatment Lupus and autoimmune diseases Systemic diseases such as hyperlipidemia and cardiovascular metabolic syndrome Severe male factor, especially non-obstructive azoospermia (sperm count less than 5 million/ml) Receive insulin E28.2 polycystic ovarian syndrome Treatment - Other Placebo Intervention group: receiving oral alpha lipoic acid capsule 600 mg daily for 2 months Control group: Receiving a placebo( containing flour) daily for two months The number of oocyte obtained. Timepoint: Two months after the start of the intervention. Method of measurement: Count the number. The number of MII oocyte obtained. Timepoint: Two months after the start of the intervention. Method of measurement: Count the number. Fertilization rate. Timepoint: Two months after the start of the intervention. Method of measurement: Count the number of formed zygote. Biochemical pregnancy. Timepoint: 14 days after embryo transfer. Method of measurement: Measurement of beta hormone serum level. Clinical pregnancy. Timepoint: 6 weeks after embryo transfer. Method of measurement: Sonography. Bandare-abbas University of Medical Sciences Approved 2022-12-12 Ethic committee of Hormozgan University of medical sciences Deputy of research and technology, campus of Hormozgan University of Medical Sciences, Imam Hossein boulevard, Bandar Abas, Iran Bandar Abbas Hormozgan Iran (Islamic Republic of)